Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression

Prostate cancer (PC) progressed to castration resistance (CRPC) is a fatal disease. CRPC tumors develop resistance to new-generation antiandrogen enzalutamide through lineage plasticity, characterized by epithelial-mesenchymal transition (EMT) and a basal-like phenotype. FOXA1 is a transcription fac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Song, Bing, Park, Su-Hong, Zhao, Jonathan C., Fong, Ka-wing, Li, Shangze, Lee, Yongik, Yang, Yeqing A., Sridhar, Subhasree, Lu, Xiaodong, Abdulkadir, Sarki A., Vessella, Robert L., Morrissey, Colm, Kuzel, Timothy M., Catalona, William, Yang, Ximing, Yu, Jindan
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355239/
https://ncbi.nlm.nih.gov/pubmed/30511964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI122367
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars